ArticleEuropean journal of immunology2004
CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice.
Article in European journal of immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus.Clinical rheumatology · 2026Article
- A MIF-p38-GSDMD inflammatory loop in keratinocytes underlies UVB-induced cutaneous lupus.Cell death & disease · 2026Article
- Mediterranean fever gene variants may prevent the development of lupus nephritis in Japanese patients with systemic lupus erythematosus.Frontiers in immunology · 2025Article
- The Dynamics of the Skin's Immune System.International journal of molecular sciences · 2019Review
- Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.The Journal of clinical investigation · 2018Article
- Pathogenesis of Skin Injury of Systemic Lupus Erythematosus.Current rheumatology reports · 2018Review
- Pathogenesis and targeted treatment of skin injury in SLE.Nature reviews. Rheumatology · 2015Review
- Langerhans Cells Maintain Local Tissue Tolerance in a Model of Systemic Autoimmune Disease.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.European journal of immunology · 2015Article
- OCH ameliorates bone marrow failure in mice via downregulation of T-bet expression.Journal of immunology research · 2014Article
- Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.Clinical and experimental medicine · 2013Review
- Human cytomegalovirus (HCMV) US2 protein interacts with human CD1d (hCD1d) and down-regulates invariant NKT (iNKT) cell activity.Molecules and cells · 2013Article
- The combination of two Sle2 lupus-susceptibility loci and Cdkn2c deficiency leads to T-cell-mediated pathology in B6.Fas(lpr) mice.Genes and immunity · 2013Article
- Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus.Clinical and experimental immunology · 2013Article
- Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus.Arthritis research & therapy · 2013Article
- Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?Clinical and experimental immunology · 2013Review
- Article
- Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.Journal of clinical immunology · 2012Article
- Modulatory function of invariant natural killer T cells in systemic lupus erythematosus.Clinical & developmental immunology · 2012Review
- Invariant natural killer T cells in rheumatic disease: a joint dilemma.Nature reviews. Rheumatology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Mechanisms responsible for the development of autoimmune skin disease in humans and animal models with lupus remain poorly understood. In this study, we have investigated the role of CD1d, an antigen-presenting molecule known to activate natural killer T cells, in the development of inflammatory dermatitis in lupus-susceptible MRL-lpr/lpr mice. In particular, we have established MRL-lpr/lpr mice carrying a germ-line deletion of the CD1d genes. We demonstrate that CD1d-deficient MRL-lpr/lpr mice, as compared with wild-type littermates, have more frequent and more severe skin disease, with increased local infiltration with mast cells, lymphocytes and dendritic cells, including Langerhans cells. CD1d-deficient MRL-lpr/lpr mice had increased prevalence of CD4(+) T cells in the spleen and liver and of TCR alpha beta (+)B220(+) cells in lymph nodes. Furthermore, CD1d deficiency was associated with decreased T cell production of type 2 cytokines and increased or unchanged type 1 cytokines. These findings indicate a regulatory role of CD1d in inflammatory dermatitis. Understanding the mechanisms by which CD1d deficiency results in splenic T cell expansion and cytokine alterations, with increased dermal infiltration of dendritic cells and lymphocytes in MRL-lpr/lpr mice, will have implications for the pathogenesis of inflammatory skin diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.